Alimera up 70% on success at last for Iluvien
This article was originally published in Scrip
Alimera's treatment for diabetic macular oedema Iluvien (fluocinolone acetonide) is set to reach its first markets in the EU, giving a 70% share price boost to the company that has endured repeated rejections for the product in the US. Shares in the company reached a day high of $4.25 and closed at $3.94 on 28 February.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.